Strata Critical Medical Inc

SRTA

Market cap $362M

Strata Critical Medical, Inc. ( SRTA ) Analyst/Investor Day November 17, 2025 2:00 PM EST Company Participants Mathew Schneider - Vice President of Investor Relations & Strategic Finance Melissa Tomkiel - Co- CEO, General Counsel & Director William Heyburn - Co- CEO, CFO & Director Scott Wunsch - Chief Executive Officer of Trinity Keith Trepanier - Chief of Safety Andrew Marreel Louis Verdetto Michael Hancock Scott Silvestry Jamie Bucio Christie Campbell Eric Moore Conference Call Participants Xuesong Wang - Morgan Stanley, Research Division Presentation Mathew Schneider Vice President of Investor Relations & Strategic Finance All right. Let's get started.

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company") is hosting its 2025 Investor Day today at the Nasdaq MarketSite in New York City. The event features presentations by leaders across the business and begins at 2:00pm ET.

Strata Critical Medical, Inc. ( SRTA ) Q3 2025 Earnings Call November 10, 2025 8:00 AM EST Company Participants Mathew Schneider - Vice President of Investor Relations & Strategic Finance William Heyburn - Co- CEO, CFO & Director Melissa Tomkiel - Co- CEO, General Counsel & Director Conference Call Participants Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Jon Hickman - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to Strata Critical Medical Fiscal Third Quarter 2025 Earnings Release Conference Call. [Operator Instructions] As a reminder, this call is being recorded.

Revenue increased 36.7% year-over-year to $49.3 million in Q3 2025 and grew 29.0% excluding the impact of the Keystone acquisition  Net loss increased to $(9.7) million in Q3 2025 versus $(5.6) million in the prior year period Medical Segment Adjusted EBITDA increased 93.5% in Q3 2025 to $7.6 million versus the prior year period and increased 80.2% excluding the impact of the Keystone acquisition (1) Medical Segment Adjusted EBITDA margin excluding Keystone increased to 15.1% in Q3 2025 (1) Raised 2025 revenue guidance to $185-195 million, reaffirmed Adjusted EBITDA range Investor Day scheduled for November 17th 2025; will introduce 2026 guidance and medium term financial targets NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the third quarter ended September 30, 2025. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only.

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical. (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the third quarter ended September 30, 2025 on Monday, November 10, 2025 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and will include a question-and-answer session for call participants.

NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), formerly known as Blade Air Mobility, Inc. (Nasdaq: BLDE), will hold an Investor Day at the Nasdaq MarketSite in New York City on Monday, November 17th 2025. The event will begin at 2:00pm ET and will include presentations by members of the management team.

OrganOx Ltd., the organ technology company tackling the world's toughest transplant challenges, announced that its metra® normothermic machine perfusion (NMP) device has received approval from the U.S. Food and Drug Administration (FDA) for operation during air transport. This marks a major milestone in the company's mission to make every organ count by supporting the broader utilization of donor organs that might otherwise be discarded due to time, geographic distance or marginal liver function1,2.

Keystone is expected to generate approximately $65 million of revenue and approximately $13 million of Adjusted EBITDA (1) in the full-year 2025, with revenue expected to grow more than 50% in 2025 versus 2024 Acquisition follows multi-year partnership between Strata and Keystone whereby Keystone has successfully recovered hundreds of organs on behalf of Strata customers $124 million acquisition represents an approximate 9x multiple of 2025 estimated Adjusted EBITDA (1) ; Keystone's go forward Free Cash Flow (1) conversion is expected to be approximately 80% NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), formerly known as Blade Air Mobility, Inc. (Nasdaq: BLDE), today announced that it has completed the acquisition of Keystone Perfusion Services LLC ("Keystone"), one of the largest organ recovery and normothermic regional perfusion ("NRP") service providers to the transplant industry and an industry leader in perfusion and other critical medical solutions for hospitals in non-transplant surgeries nationwide.

NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), formerly known as Blade Air Mobility, Inc. (Nasdaq: BLDE) today announced that Will Heyburn, Co-Chief Executive Officer and Chief Financial Officer, will present at the 2025 Jefferies Industrials Conference on Thursday, Sept 4, 2025 at 11:30am ET. A webcast of the event will be available at the link here. A replay will be available shortly after the conclusion of the presentation on the investor relations section of the Company's website at https://ir.stratacritical.com/news-events.

NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), formerly known as Blade Air Mobility, Inc. (Nasdaq: BLDE), today announced the successful closing of the previously announced divestiture of the Company's Passenger business to Joby Aviation, Inc. (NYSE: JOBY). Joby has elected to pay the up-front consideration in stock. The Company may receive up to an additional $35.0 million in consideration based on maintaining certain employee retention and financial performance targets during the 18 and 12 months, respectively, following today's closing, as well as the release of up to $10.0 million in indemnity holdbacks, payable in cash or stock at Joby's election.